Free Trial

Pernod Ricard (Baa1, BBB+, BBB+; S) {RI FP Equity} 3Q Results

CONSUMER CYCLICALS

Weak Q3, with US and Europe dragging, China recovery not there in domestic numbers but travel retail did recovery strongly. Pernod has been pushing recovery down the road (see 1H results) and is doing the same again pointing to a Q4 recovery to drag up organic -2% YTD sales to flat levels. Well guided capex bump, a now interim dividend bump and €300m ongoing buyback is on track to take out most of FCF this year.

  • Organic sales over Q3 were flat (c+2.8%) at €2.35b (c€2.48b). Gross/reported was -2%.
  • Heavy fall in US (-7% vs. c-4%) & Europe (-6% vs. c-3%) while Asia & Rest of World came in at +8% vs. c+9.2%. China fell -12% in Q3 (-9% YTD) on "challenging macro environment", though it did report a +38% in travel retail on Chinese travellers. Strength in India & double digit growth in Japan.
  • Guidance is largely unch; "broadly stable" organic net sales, EBIT margins expanding driving growth of +1%, Capex unch at €800m & FCF left broad at 'reflecting lower EBIT & increase capex'. Reaffirms medium term target of +4-7% sales growth.
  • Equity payouts this year include €300m buyback & interim dividend looks sizeable and above consensus (c€2.06/share) at €2.35/share (~€600m) - might be compensating for buyback cuts earlier this year. Final tends to be €2.5/share+/~€650m, and if so will take out most of current FCF (c€1.35b).

Keep reading...Show less
232 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Weak Q3, with US and Europe dragging, China recovery not there in domestic numbers but travel retail did recovery strongly. Pernod has been pushing recovery down the road (see 1H results) and is doing the same again pointing to a Q4 recovery to drag up organic -2% YTD sales to flat levels. Well guided capex bump, a now interim dividend bump and €300m ongoing buyback is on track to take out most of FCF this year.

  • Organic sales over Q3 were flat (c+2.8%) at €2.35b (c€2.48b). Gross/reported was -2%.
  • Heavy fall in US (-7% vs. c-4%) & Europe (-6% vs. c-3%) while Asia & Rest of World came in at +8% vs. c+9.2%. China fell -12% in Q3 (-9% YTD) on "challenging macro environment", though it did report a +38% in travel retail on Chinese travellers. Strength in India & double digit growth in Japan.
  • Guidance is largely unch; "broadly stable" organic net sales, EBIT margins expanding driving growth of +1%, Capex unch at €800m & FCF left broad at 'reflecting lower EBIT & increase capex'. Reaffirms medium term target of +4-7% sales growth.
  • Equity payouts this year include €300m buyback & interim dividend looks sizeable and above consensus (c€2.06/share) at €2.35/share (~€600m) - might be compensating for buyback cuts earlier this year. Final tends to be €2.5/share+/~€650m, and if so will take out most of current FCF (c€1.35b).

Keep reading...Show less